Minoxidil: Topical and Low-Dose Oral for Hair Loss

Minoxidil is not a peptide. It appears in this formulary because it is the first-line pharmacologic treatment for androgenetic alopecia and is used alongside peptide approaches such as those covered in our peptides for hair growth guide. Any clinician offering hair restoration needs it well understood.

This guide situates Minoxidil within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

From blood pressure drug to hair treatment

Minoxidil was developed as an antihypertensive, a potent vasodilator for severe hypertension. Patients taking it developed hypertrichosis — unwanted hair growth — and that adverse effect became the basis for an entire product category.

Its mechanism in hair remains incompletely understood, which is worth admitting rather than glossing. It is an ATP-sensitive potassium channel opener, producing vasodilation and increased perifollicular blood flow. It also appears to act more directly on the follicle: prolonging the anagen (growth) phase, shortening telogen, and increasing follicle size, with effects on dermal papilla cells and possibly on prostaglandin and growth factor signalling.

Crucially, minoxidil is a prodrug. It must be converted to minoxidil sulfate by follicular sulfotransferase enzymes to be active. Sulfotransferase activity varies substantially between individuals, and low activity is a leading explanation for why some patients respond poorly to topical treatment despite correct use.

Topical minoxidil in practice

Topical minoxidil is available over the counter for androgenetic alopecia in both men and women, in solution and foam formulations. The foam avoids propylene glycol, which is responsible for much of the irritation and contact dermatitis seen with solutions.

Three points determine whether a patient succeeds with it.

First, the shedding phase. In the early weeks many patients shed noticeably, sometimes alarmingly. This happens because minoxidil pushes telogen follicles into a new anagen phase, and the resting hairs are ejected as new ones grow. It is a sign the drug is working, and patients not warned about it frequently quit at precisely the wrong moment. This single piece of counselling changes outcomes.

Second, timeline. Meaningful assessment requires four to six months, and full effect longer.

Third, indefinite use. Minoxidil does not cure androgenetic alopecia. Discontinuation leads to loss of the gained hair within months, returning the patient to their untreated trajectory. That commitment should be clear before starting.

The shift to low-dose oral minoxidil

The most significant recent development in hair medicine is the adoption of low-dose oral minoxidil — typically a small fraction of antihypertensive dosing — used off-label for androgenetic alopecia and other hair loss.

Its advantages are practical and real: no messy topical application, no scalp irritation, better adherence, and it bypasses the sulfotransferase problem since conversion occurs systemically. Published series report good efficacy and tolerability at low doses.

The trade-offs are systemic. Hypertrichosis — unwanted hair on the face, arms and elsewhere — is the most common effect and the most common reason for discontinuation, particularly in women. Fluid retention, ankle edema, postural symptoms and tachycardia occur. At antihypertensive doses minoxidil carries a boxed warning regarding pericardial effusion; this is not reported at low doses but underlies the caution.

Appropriate practice includes baseline cardiovascular assessment, care in patients with cardiac or renal disease, and review of interacting antihypertensives. This is off-label prescribing of a systemic cardiovascular drug, and it deserves to be treated as such rather than as a routine cosmetic intervention.

Where it sits in treatment

Minoxidil and finasteride act through entirely different mechanisms — one prolongs the growth phase, the other removes the hormonal driver of miniaturization — and are frequently combined for that reason, with better results than either alone.

Minoxidil is also used alongside procedural approaches including microneedling and platelet-rich plasma, and around hair transplantation.

For patients seeking regenerative or peptide-based approaches, minoxidil remains the intervention with the strongest evidence in this space, and it is the appropriate baseline against which any adjunct should be judged.